Tumour necrosis factor-α blockers in rheumatoid arthritis -: Review of the clinical experience

被引：35

作者：

Richard-Miceli, C

Dougados, M ^{[1
]}

机构：

[1] Univ Paris 05, Hop Cochin, Rhumatol Clin, Assistance Publ Hop Paris, F-75679 Paris 14, France

[2] Hop St Louis, Ctr Etud Polymorphisme Humain, Paris, France

来源：

BIODRUGS | 2001年 / 15卷 / 04期

关键词：

D O I：

10.2165/00063030-200115040-00005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tumour necrosis factor (TNF)-alpha has been found to play a central role in the pathogenesis of rheumatoid arthritis, leading to development of novel drug therapies that neutralise the deleterious effects of this cytokine. This new concept of immunobiological treatment of rheumatoid arthritis has yielded successful results. Although the 2 currently available TNF alpha blockers, infliximab and etanercept, differ in structure, mechanism of action and pharmacokinetics. they have provided similar benefits both in clinical improvement and in slowing and even arresting the progression of radiographic damage. This therapeutic response seems to be unequalled by 'conventional treatments in rheumatoid arthritis, and is incontestably a turning point in the therapeutic management of this disease.

引用

收藏

页码：251 / 259

页数：9

相关论文

共 24 条

[1] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].

Bathon, JM ;

Martin, RW ;

Fleischmann, RM ;

Tesser, JR ;

Schiff, MH ;

Keystone, EC ;

Genovese, MC ;

Wasko, MC ;

Moreland, LW ;

Weaver, AL ;

Markenson, J ;

Finck, BK .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593

[2] Antibodies to tumour necrosis factor α as treatment for Crohn's disease [J].

Bell, S ;

Kamm, MA .

LANCET, 2000, 355 (9207) :858-860

[3]

BRENNAN FM, 1989, LANCET, V2, P244

[4]

*CENT, 1999, INFL REM PRESCR INF

[5] TUMOR-NECROSIS-FACTOR (CACHECTIN) IS AN ENDOGENOUS PYROGEN AND INDUCES PRODUCTION OF INTERLEUKIN-1 [J].

DINARELLO, CA ;

CANNON, JG ;

WOLFF, SM ;

BERNHEIM, HA ;

BEUTLER, B ;

CERAMI, A ;

FIGARI, IS ;

PALLADINO, MA ;

OCONNOR, JV .

JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (06) :1433-1450

[6]

*IMM CORP, 2001, ET ENBR PRESCR INF

[7] INFLUENCE OF METHOTREXATE AND AZATHIOPRINE ON RADIOLOGIC PROGRESSION IN RHEUMATOID-ARTHRITIS - A RANDOMIZED, DOUBLE-BLIND-STUDY [J].

JEURISSEN, MEC ;

BOERBOOMS, AMT ;

VANDEPUTTE, LBA ;

DOESBURG, WH ;

LEMMENS, AM .

ANNALS OF INTERNAL MEDICINE, 1991, 114 (12) :999-1004

[8]

Jones M, 1996, BRIT J RHEUMATOL, V35, P738

[9] Infliximab and methotrexate in the treatment of rheumatoid arthritis [J].

Lipsky, PE ;

van der Heijde, DMFM ;

St Clair, EW ;

Furst, DE ;

Breedveld, FC ;

Kalden, JR ;

Smolen, JS ;

Weisman, M ;

Emery, P ;

Feldmann, M ;

Harriman, GR ;

Maini, RN .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1594-1602

[10] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].

Maini, R ;

St Clair, EW ;

Breedveld, F ;

Furst, D ;

Kalden, J ;

Weisman, M ;

Smolen, J ;

Emery, P ;

Harriman, G ;

Feldmann, M ;

Lipsky, P .

LANCET, 1999, 354 (9194) :1932-1939